CN113519624A - 一种提高航天员免疫力和抗病毒能力的营养配方及制备方法 - Google Patents
一种提高航天员免疫力和抗病毒能力的营养配方及制备方法 Download PDFInfo
- Publication number
- CN113519624A CN113519624A CN202010305093.4A CN202010305093A CN113519624A CN 113519624 A CN113519624 A CN 113519624A CN 202010305093 A CN202010305093 A CN 202010305093A CN 113519624 A CN113519624 A CN 113519624A
- Authority
- CN
- China
- Prior art keywords
- parts
- mixture
- igg
- astronauts
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 27
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 25
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 241000283690 Bos taurus Species 0.000 claims abstract description 15
- QHBZHVUGQROELI-UHFFFAOYSA-N Royal Jelly acid Natural products OCCCCCCCC=CC(O)=O QHBZHVUGQROELI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 210000003022 colostrum Anatomy 0.000 claims abstract description 15
- 235000021277 colostrum Nutrition 0.000 claims abstract description 15
- KUPHXIFBKAORGY-UHFFFAOYSA-N 2-amino-3-iodo-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C(N)=C1I KUPHXIFBKAORGY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940109850 royal jelly Drugs 0.000 claims abstract description 14
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 13
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims abstract description 13
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000787 lecithin Substances 0.000 claims abstract description 13
- 229940067606 lecithin Drugs 0.000 claims abstract description 13
- 235000010445 lecithin Nutrition 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 13
- 241000208340 Araliaceae Species 0.000 claims abstract description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 12
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 12
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 12
- 235000008434 ginseng Nutrition 0.000 claims abstract description 12
- 239000008176 lyophilized powder Substances 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 241001529821 Agastache Species 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 241000965254 Apostichopus japonicus Species 0.000 claims abstract description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims abstract description 5
- 238000002791 soaking Methods 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 16
- 241000251511 Holothuroidea Species 0.000 claims description 11
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 11
- 235000008397 ginger Nutrition 0.000 claims description 11
- 244000197580 Poria cocos Species 0.000 claims description 10
- 235000008599 Poria cocos Nutrition 0.000 claims description 10
- 229920002498 Beta-glucan Polymers 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 4
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 4
- 241001162994 Rugosus Species 0.000 claims description 4
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 4
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000011265 semifinished product Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 240000001949 Taraxacum officinale Species 0.000 claims 2
- 235000013305 food Nutrition 0.000 abstract description 10
- 229920002307 Dextran Polymers 0.000 abstract description 4
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000012467 final product Substances 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241000700605 Viruses Species 0.000 description 9
- 241000234314 Zingiber Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010024642 Listless Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 241000245665 Taraxacum Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000017971 listlessness Diseases 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010049976 Impatience Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- QHBZHVUGQROELI-SOFGYWHQSA-N (E)-10-hydroxydec-2-enoic acid Chemical compound OCCCCCCC\C=C\C(O)=O QHBZHVUGQROELI-SOFGYWHQSA-N 0.000 description 1
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical group [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 241001327634 Agaricus blazei Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 235000000665 Lycianthes asarifolia Nutrition 0.000 description 1
- 241000866517 Lycianthes asarifolia Species 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001467018 Typhis Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- BWLSGGIBIVPZOO-UHFFFAOYSA-N dithiane 1,1,2,2-tetraoxide Chemical compound O=S1(=O)CCCCS1(=O)=O BWLSGGIBIVPZOO-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- -1 royal jelly acid Chemical compound 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000010119 systemic immune function Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/206—Colostrum; Human milk
Abstract
本发明提供了一种提高航天员免疫力和抗病毒能力的营养配方及制备方法,涉及食品及功能性食品领域。该产品含有牛初乳冻干粉(IGG20%)、卵磷脂、海参粉、N‑乙酰神经氨酸、人参、酵母-β-葡聚糖、低聚半乳糖、蜂王浆、蒲公英、茯苓、甘草、生姜、陈皮、藿香。其制备方法为,药食同源的人参、蒲公英、茯苓、甘草、生姜、陈皮、藿香经浸泡、煎煮、提取而得浓缩液,再与牛初乳冻干粉(IGG20%)、卵磷脂、海参粉、N‑乙酰神经氨酸、酵母-β-葡聚糖、低聚半乳糖、蜂王浆(10‑羟基‑2‑癸烯酸2.0%)经调配、灌装得成品。该产品添加牛初乳冻干粉(IGG20%)和蜂王浆(10‑羟基‑2‑癸烯酸2.0%),在指标选择上非常严格,并具有厂家提供的功能性及临床实验报告。在上述各原料组分的相互协同作用下,对在特殊环境下的工作人员尤其是航天员具有较好的提高免疫力和抗病毒能力。
Description
技术领域
本发明涉及功能性食品及食品领域,具体地说,涉及一种提高航天员免疫力和抗病毒能力的营养配方及制备方法。
背景技术
2020年新冠肺炎给我们的生活、工作等方面带来了一定的影响,也让每一个中国人重新认识了自身体质的情况,那么我们要知道什么是免疫力,什么是病毒:免疫力是人体自身的防御机制,是人体识别和消灭外来侵入的任何异物(病毒、细菌等);处理衰老、损伤、死亡、变性的自身细胞以及识别和处理体内突变细胞和病毒感染细胞的能力。病毒(virus)是由一个核酸分子(DNA或RNA)与蛋白质构成的非细胞形态的营寄生生活的生命体。其主要特点是:①形体极其微小,必须在电子显微镜下才能观察;②没有细胞构造,其主要成分仅为核酸和蛋白质两种;③一种病毒只含一种核酸(DNA或RNA)④体内无酶系,只能利用宿主活细胞内现成代谢系统合成自身的核酸和蛋白质成分;⑤以核酸和蛋白质等“元件”的装配实现其大量繁殖;⑥在离体条件下,能以无生命的生物大分子状态存在,并长期保持其侵染活力;⑦对一般抗生素不敏感,但对干扰素敏感;⑧有些病毒的核酸还能整合到宿主的基因组中,并诱发潜伏性感染。认识这些对我们在提升免疫力和抗病毒能力上有更好的理论指导作用。
在这次疫情中,我们要感谢那些工作在一线的医护人员,是他们舍弃了小家在舍身忘我的保护着祖国的大家庭,因此我们这些致力于大健康产业的研发人员要为奋斗在特殊岗位的人员提供有特殊功能的配方营养食品,保证他们的健康。在我国一次次世界领先技术的出现,一次次科技进步的突破,也都少不了我们中国航天事业的巨大贡献,那些勇敢的航天员们。
航天员是一种特殊的在极端条件下工作的人,他们需要在失重、噪声、振动、辐射、昼夜节律改变、狭小空间等特殊环境下作业和生活。研究表明,航天环境对人体的系统免疫功能、机体抗病毒能力等均有不利影响,而为了增强航天员在太空特殊环境下的提高免疫功能及机体抗病毒能力的进程,开发一种具有提高免疫力和抗病毒功效的航天食品尤为关键。
发明内容
鉴于此,本发明的主要目的在于提供一种提高航天员免疫力和抗病毒能力的营养配方及制备方法。
具体来说,本发明提供一种提高航天员免疫力和抗病毒能力的营养配方,原料组分以重量计:
牛初乳冻干粉(IGG20%):5-9份;
卵磷脂:3-6份;
海参粉:5-8份;
N-乙酰神经氨酸:2-5份;
人参:1-3份;
酵母-β-葡聚糖:1-5份;
低聚半乳糖:1-3份;
蜂王浆(10-羟基-2-癸烯酸2.0%):5-9份;
进一步地本发明提供一种提高航天员免疫力和抗病毒能力的营养配方,原料组分以重量计:
牛初乳冻干粉(IGG20%):8份;
卵磷脂:5份;
海参粉:6份;
N-乙酰神经氨酸:3份;
人参:2份;
酵母-β-葡聚糖:3份;
低聚半乳糖:2份;
蜂王浆(10-羟基-2-癸烯酸2.0%):8份;
蒲公英:8份;
茯苓:8份;
甘草:8份;
生姜:6份;
陈皮:6份;
藿香:3份。
进一步地本发明提供一种提高航天员免疫力和抗病毒能力的营养配方,原料组分中所述的牛初乳冻干粉(IGG20%)和蜂王浆(10-羟基-2-癸烯酸2.0%)严格按照规定的指标优选。
进一步地本发明提供一种提高航天员免疫力和抗病毒能力的营养配方及制备方法包括以下步骤:
(1)将人参、蒲公英、茯苓、甘草、生姜、陈皮、藿香在常温水中浸泡60-120分钟;
(2)将(1)中加入药材总量的6-10倍的水,加热煮沸,文火煎煮40-60分钟,过滤得到混合提取液;
(3)按照(2)步骤,在同等条件下,在提取2次,所得混合提取液备用;
(4)将(2)和(3)所得混合提取液合并,在65-75℃减压浓缩至相对密度为1.01-1.08,的水提混合浓缩液;
(5)在上述(4)混合浓缩液中加入牛初乳冻干粉(IGG20%)、蜂王浆(10-羟基-2-癸烯酸2.0%)、卵磷脂、海参粉、N-乙酰神经氨酸,混合均匀;
(6)将 (5)混合溶液过滤后,冷却到室温,加入酵母-β-葡聚糖、低聚半乳糖调配好口感,搅拌均匀;
(7)将(6)搅拌均匀的混合液经自动灌装机灌装、轧盖;
(8)将(7)的到的半成品放置电器两用压力灭菌锅中,与108℃±1灭菌40min,即得成品。
本发明与现有技术相比,把抗病毒和提高免疫力相结合,弥补了市场的空缺,通过协同增效的理论大大增加了营养成分的利用度,比单一的补充更具有优越性。本发明的营养配方中牛初乳冻干粉中含有20%IGG,蜂王浆中含有2.0%的10-羟基-2-癸烯酸,对提高免疫力和抗病毒能力的针对性很强。
牛初乳冻干粉直接采用母牛产犊后3天内的乳汁,在不破坏原有乳汁的营养成分状态下采用FD冻干技术制得。牛初乳亦含有大量的免疫球蛋白(IGG),免疫球蛋白特异性地结合抗原和特异性识别抗原分子,在体内,抗体和抗原结合后可直接发挥抗病毒效应。
蜂王浆能够杀灭肝炎病毒,并且能抑制病毒在肝脏细胞内复制,其中的黄酮类等物质有降低转氨酶作用,促进肝细胞再生,防止肝硬变,蜂王浆的抗菌谱为大肠杆菌、金黄色葡萄球 伤寒杆菌、链球菌、变形杆菌、枯草杆菌、结核杆菌、星状发癣菌和表皮癣菌等,在天然的状况下,它的抗菌消炎性最强。蜂王浆有促进造血功能作用,可提高抗病力,蜂王浆含蛋白质激素和天然抗生素,涂抹治疗烫伤时能起到防止感染、促进细胞生成、愈后不留疤痕的作用,蜂王浆中含有 免疫球蛋白,能明显的提高人体免疫力,蜂王浆中的10-羟基-2-癸烯酸,即王浆酸有抗菌、消炎、止痛的作用,可抑制大肠杆菌、化脓球菌、表皮癣菌、结核杆菌等十余种细菌生长。
卵磷脂(lecithin)又称蛋黄素,被誉为与蛋白质、维生素并列的“第三营养素”。社会竞争日趋激烈,人们长期处在紧张的环境和种种压力下,常患有焦虑、急躁、易怒、失眠、耳鸣等症,即植物神经紊乱,通常被称为神经衰弱。经常补充卵磷脂,可使大脑神经及时得到营养补充,保持健康的工作状态,利于消除疲劳,激化脑细胞,改善因神经紧张而引起的免疫力低下、机体防御功能降低、急躁、易怒、失眠等症,起到协同增效的效果。
据《本草纲目拾遗》中记载:海参,味甘咸,补肾,益精髓,摄小便,壮阳疗痿,其性温补,足敌人参,故名海参。海参具有提高免疫力、延缓性腺衰老,防止动脉硬化以及抗肿瘤等作用。随着海参价值知识的普及,海参逐渐进入百姓餐桌。
N—乙酰神经氨酸是一种能使唾液产生光滑感觉的负电荷离子。它不仅据有"诱导"入侵病菌的作用,认知是神经节苷脂的传递递质,并且是大脑的组成部分。N—乙酰神经氨酸可以阻止病菌入侵。N—乙酰神经氨酸同时也是流感病毒的受体,是流感病毒结合在黏液细胞中的结合位点。
人参性味甘、微苦,微温,归脾、肺、心、肾经,大补元气,复脉固脱,补脾益肺,生津养血,安神益智。用于体虚欲脱,肢冷脉微,脾虚食少,肺虚喘咳,津伤口渴,内热消渴,气血亏虚,久病虚羸,惊悸失眠,阳痿宫冷。
酵母葡聚糖是第一个被发现具有免疫活性的葡聚糖。美国哈佛大学、图伦大学、华盛顿大学以及美国空军放射生物学研究所等科研机构从姬松茸发酵提纯β-1,3-葡聚糖并进行研究都证实:天然酵母葡聚糖具有的独特靶向作用,能够定向清除体内毒素,同时提高巨噬细胞的吞噬能力达10倍以上,使人体免疫系统迅速达到最佳平衡,无任何药物的毒副作用,有效预防各类慢性疾病的发生。
低聚半乳糖以乳清为原料,经酶解合成喷雾干燥等工艺精制而成的乳白或微黄色粉末,是母乳化的功能性低聚糖。低聚半乳糖对肠内的益生菌群有很强的增殖作用,同时具有和植物纤维的相同效用,可促进肠胃蠕动,改善肠道功能。与李兰娟院士在预防治疗新冠肺炎方案中提出的四抗两平衡中微生态平衡相适应。
蒲公英植物体中含有蒲公英醇、蒲公英素、胆碱、有机酸、菊糖等多种健康营养成分。性味甘,微苦,寒。归肝、胃经。有利尿、缓泻、退黄疸、利胆等功效。治热毒、痈肿、疮疡、内痈、目赤肿痛、湿热、黄疸、小便淋沥涩痛、疔疮肿毒,乳痈,瘰疬,牙痛,目赤,咽痛,肺痈,肠痈,湿热黄疸,热淋涩痛。治急性乳腺炎,淋巴腺炎,瘰疬,疔毒疮肿,急性结膜炎,感冒发热,急性扁桃体炎,急性支气管炎,胃炎,肝炎,胆囊炎,尿路感染等。蒲公英可生吃、炒食、做汤,是药食兼用的植物。
茯苓,中药名。为多孔菌科卧孔属真菌茯苓的干燥菌核。产云南者称“云苓”,质较优。具有利水消肿,渗湿,健脾,宁心的功效。主治水肿,痰饮,脾虚泄泻,心悸,失眠。
甘草 性味甘,平,归心、肺、脾、胃经,补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
生姜,姜的根茎(干姜)、栓皮(姜皮)、叶(姜叶)均可入药。性温,其特有的“姜辣素”能刺激胃肠黏膜,使胃肠道充血,消化能力增强,能有效地治疗吃寒凉食物过多而引起的腹胀、腹痛、腹泻、呕吐等。 吃过生姜后,人会有身体发热的感觉,这是因为它能使血管扩张,血液循环加快,促使身上的毛孔张开,这样不但能把多余的热带走,同时还把体内的病菌、寒气一同带出。当身体吃了寒凉之物,受了雨淋或在空调房间里呆久后,吃生姜就能及时消除因肌体寒重造成的各种不适。
陈皮性味 苦、辛,温。归肺、脾经, 理气健脾,燥湿化痰,用于脘腹胀满,食少吐泻,咳嗽痰多。
藿香性味辛,微温。归脾、胃、肺经,芳香化浊,和中止呕,发表解暑。用于湿浊中阻,脘痞呕吐,暑湿表证,湿温初起,发热倦怠,胸闷不舒,寒湿闭暑,腹痛吐泻,鼻渊头痛。
本发明根据中医理论,肾乃先天之本,脾为后天之源,用中药材将脾肾坚固,在施之以靶位,从根源上解决提高免疫力和抗病毒能力,可以称为中西相结合的引例,弥补了提高免疫力和抗病毒能力这一技术上的空缺。
具体实施方式
以下对本发明的技术方案做进一步的说明。
本实施例一种提高航天员免疫力和抗病毒能力的营养配方中各原料份数:
卵磷脂:5份;
海参粉:6份;
N-乙酰神经氨酸:3份;
人参:2份;
酵母-β-葡聚糖:3份;
低聚半乳糖:2份;
蜂王浆(10-羟基-2-癸烯酸2.0%):8份;
蒲公英:8份;
茯苓:8份;
甘草:8份;
生姜:6份;
陈皮:6份;
藿香:3份。
本实施例一种提高航天员免疫力和抗病毒能力的营养配方及制备方法,按照以下步骤制备:
(1)将人参、蒲公英、茯苓、甘草、生姜、陈皮、藿香在常温水中浸泡60-120分钟;
(2)将(1)中加入药材总量的6-10倍的水,加热煮沸,文火煎煮40-60分钟,过滤得到混合提取液;
(3)按照(2)步骤,在同等条件下,在提取2次,所得混合提取液备用;
(4)将(2)和(3)所得混合提取液合并,在65-75℃减压浓缩至相对密度为1.01-1.08,的水提混合浓缩液;
(5)在上述(4)混合浓缩液中加入牛初乳冻干粉(IGG20%)、蜂王浆(10-羟基-2-癸烯酸2.0%)、卵磷脂、海参粉、N-乙酰神经氨酸,混合均匀;
(6)将 (5)混合溶液过滤后,冷却到室温,加入酵母-β-葡聚糖、低聚半乳糖调配好口感,搅拌均匀;
(7)将(6)搅拌均匀的混合液经自动灌装机灌装、轧盖;
(8)将(7)的到的半成品放置电器两用压力灭菌锅中,与108℃±1灭菌40min,即得成品。
小鼠抗病毒能力实验:
取小鼠24只,随机分成2组,其中1组做抗病毒能力实验,一组做空白对照实验。同时给2组小鼠同样食物喂养,实验组每日2次,每次给予0.8ml样液注射,经过22天后,分别给予空白组和实验组注入流感病毒,经过一周的观察,实验组有3只小鼠在观察的第4天和第5天出现感冒症状,空白组有10只在观察的第3天、第4天和地5天都出现不同程度的感冒症状,由此可以看出此营养配方有一定的抗病毒作用。
小鼠提高免疫力实验:
取小鼠24只,随机分成2组,其中1组做提高免疫力实验,一组做空白对照实验。同时给2组小鼠同样食物喂养,实验组每日3次,每次给予0.8ml样液注射,经过22天后,分别将空白组和实验组给予低微剂量的四亚甲基二砜四氨,每一此次同食物一起进食,经过一周的观察,实验组有2只小鼠在观察的第3天和第4天出现无精神萎靡状态,无死亡,空白组8只在观察的第3天、第4天和地5天都出现不同程度的无精神萎靡状态,死亡2只,由此可以看出此营养配方有一定的提高免疫力的作用。
以上描述了本发明的主要特征和本发明的优点,尽管参照最佳实施例对本发明进行了详细的阐述,但不受上述实施例的限制,本行业的技术人员应该了解,可以对本发明的技术方案进行各种变动、修饰或者等同替换,同时不脱离本发明技术方案的精神和范围的,其均应当属于本发明的权利要求保护范围之中。
Claims (4)
1.一种提高航天员免疫力和抗病毒能力的营养配方,其特征在于,原料组分以重量计:
牛初乳冻干粉(IGG20%):5-9份;
卵磷脂:3-6份;
海参粉:5-8份;
N-乙酰神经氨酸:2-5份;
人参:1-3份;
酵母-β-葡聚糖:1-5份;
低聚半乳糖:1-3份;
蜂王浆(10-羟基-2-癸烯酸2.0%):5-9份;
蒲公英:8份;
茯苓:8份;
甘草:8份;
生姜:6份;
陈皮:6份;
藿香:3份。
2.根据权利要求1所述的组合物,其特征在于,原料组分以重量计:
牛初乳冻干粉(IGG20%):8份;
卵磷脂:5份;
海参粉:6份;
N-乙酰神经氨酸:3份;
人参:2份;
酵母-β-葡聚糖:3份;
低聚半乳糖:2份;
蜂王浆(10-羟基-2-癸烯酸2.0%):8份;
蒲公英:8份;
茯苓:8份;
甘草:8份;
生姜:6份;
陈皮:6份;
藿香:3份。
3.根据权利要求1和2所述的组合物,其特征在于,原料组分中所述的牛初乳冻干粉(IGG20%)和蜂王浆(10-羟基-2-癸烯酸2.0%)严格按照规定的指标优选。
4.一种提高航天员免疫力和抗病毒能力的营养配方及制备方法,其特征在于,按照以下步骤制备:
(1)将人参、蒲公英、茯苓、甘草、生姜、陈皮、藿香在常温水中浸泡60-120分钟;
(2)将(1)中加入药材总量的6-10倍的水,加热煮沸,文火煎煮40-60分钟,过滤得到混合提取液;
(3)按照(2)步骤,在同等条件下,在提取2次,所得混合提取液备用;
(4)将(2)和(3)所得混合提取液合并,在65-75℃减压浓缩至相对密度为1.01-1.08,的水提混合浓缩液;
(5)在上述(4)混合浓缩液中加入牛初乳冻干粉(IGG20%)、蜂王浆(10-羟基-2-癸烯酸2.0%)、卵磷脂、海参粉、N-乙酰神经氨酸,混合均匀;
(6)将 (5)混合溶液过滤后,冷却到室温,加入酵母-β-葡聚糖、低聚半乳糖调配好口感,搅拌均匀;
(7)将(6)搅拌均匀的混合液经自动灌装机灌装、轧盖;
(8)将(7)的到的半成品放置电器两用压力灭菌锅中,与108℃±1灭菌40min,即得成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010305093.4A CN113519624A (zh) | 2020-04-17 | 2020-04-17 | 一种提高航天员免疫力和抗病毒能力的营养配方及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010305093.4A CN113519624A (zh) | 2020-04-17 | 2020-04-17 | 一种提高航天员免疫力和抗病毒能力的营养配方及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113519624A true CN113519624A (zh) | 2021-10-22 |
Family
ID=78123285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010305093.4A Pending CN113519624A (zh) | 2020-04-17 | 2020-04-17 | 一种提高航天员免疫力和抗病毒能力的营养配方及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113519624A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4011383A1 (en) * | 2020-12-11 | 2022-06-15 | Lytone Enterprise, Inc. | Composition for modulating immunity and the use thereof |
CN115777944A (zh) * | 2023-02-10 | 2023-03-14 | 北京衡美金叶营养健康科技有限公司 | 增强身体防御力的组合物及其制备方法和应用 |
-
2020
- 2020-04-17 CN CN202010305093.4A patent/CN113519624A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4011383A1 (en) * | 2020-12-11 | 2022-06-15 | Lytone Enterprise, Inc. | Composition for modulating immunity and the use thereof |
CN115777944A (zh) * | 2023-02-10 | 2023-03-14 | 北京衡美金叶营养健康科技有限公司 | 增强身体防御力的组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104161181A (zh) | 一种抗猪细菌性疾病的饲料添加剂、制备方法及应用 | |
CN106822890A (zh) | 一种用于防治断奶仔猪腹泻的药物组合物及其制备方法和应用 | |
CN113519624A (zh) | 一种提高航天员免疫力和抗病毒能力的营养配方及制备方法 | |
CN112057560A (zh) | 一种增强免疫力的灵芝孢子石斛组合物及其制备方法与应用 | |
CN103083510A (zh) | 一种提高禽免疫功能的中药口服液及其制备方法 | |
CN103393908B (zh) | 治疗系统性红斑狼疮及风湿病的制品及其制备方法 | |
CN110664860B (zh) | 一种增强免疫力的组合物及其制备方法 | |
CN104161208A (zh) | 一种抗鸡细菌性疾病的饲料添加剂、制备方法及应用 | |
KR102095621B1 (ko) | 식품 첨가물의 제조방법 | |
CN102078600B (zh) | 抗癌复方灵芝组合物、其用途和包含其的药物组合物 | |
CN104161207A (zh) | 一种抗鸭细菌性疾病的饲料添加剂、制备方法及应用 | |
CN103933146A (zh) | 一种可调节人体免疫力的花粉制品 | |
CN112042846A (zh) | 一种增强免疫抑制肿瘤的沙棘固体饮料及其制备方法 | |
CN112704234A (zh) | 一种含有复合肽和益生菌的营养组合物及其制备方法 | |
CN103784600A (zh) | 增强貉子免疫力的中草药口服液 | |
CN1112012A (zh) | 一种生物口服液 | |
CN106344645A (zh) | 禽用中药免疫增强剂及制备方法 | |
CN106727733B (zh) | 一种鲜冬虫夏草抗肿瘤化疗的联合药物及其应用 | |
KR20080093486A (ko) | 동물의 면역능을 증강시키는 신규한 청피 추출물 및 그용도 | |
CN1265820C (zh) | 兽用复方白毛藤注射剂 | |
KR20080093488A (ko) | 시호 추출물을 유효성분으로 하는 면역 증강용 조성물 | |
CN104187168B (zh) | 一种预防鹌鹑冷应激性肠炎的复合预混料 | |
CN101104054B (zh) | 一种治疗消化系统疾病的口服液的制备方法 | |
CN117357627A (zh) | 一种提高家禽机体免疫力的复合药物及其制备方法和应用 | |
CN113368155A (zh) | 连翘益生菌发酵物及其在制备防治畜禽病毒性疾病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211022 |